Bimeda today announced the completion of its acquisition of selected non-sterile manufacturing assets at Dechra’s Pomona, California facility.
The acquisition strengthens Bimeda’s manufacturing capacity and enhances supply continuity for key products, while establishing an expanded U.S. manufacturing platform to support future growth. Bimeda and Dechra will work together to ensure a structured and seamless transition of operations over the coming months.
“This acquisition reinforces our commitment to veterinarians and animal owners by strengthening supply and increasing manufacturing flexibility for key products. It enhances our production capability and further establishes our U.S. manufacturing presence as a platform for long-term growth,” said Gavin Tierney, CEO of Bimeda Americas.
Integration activities are now underway and will be completed in a phased and controlled manner in collaboration with the Dechra team.
About Bimeda
Bimeda is a global animal health company providing high-quality veterinary pharmaceuticals and solutions to support the health and wellbeing of animals. With a focus on manufacturing excellence, supply reliability, and customer partnership, Bimeda serves customers across multiple regions with a broad portfolio of products.
For more information, visit www.bimeda.com
About Dechra
Dechra is a global specialist in veterinary pharmaceuticals and related products. Its expertise includes the development, manufacture, marketing, and sales of high-quality products exclusively for veterinarians worldwide.
For more information, visit www.dechra.com
Media Contact
